Acipimox

CLINICAL USE

Hyperlipidaemia

DOSE IN NORMAL RENAL FUNCTION

250 mg 2 or 3 times daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
154.1

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
0

%Excreted unchanged in urine &nbsp &nbsp :
86–90

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
0.3–0.4

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
2/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

40–80 250 mg daily
20–40 250 mg alternate days.
<20
See ‘Other Information’

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
Likely dialysability. Dose as in
GFR<20 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
Dialysed. Dose as in
GFR<20 mL/min

HDF/high flux &nbsp :
Dialysed. Dose as in
GFR<20 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:
Dialysed. Dose as in
GFR=20–40 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Take with or after meals

OTHER INFORMATION

Females are twice as likely as males to

suffer from side effects, e.g. flushing,
pruritus and skin rashes

Doses up to 1200 mg have been given

safely for long periods
After a 5 hour dialysis 70% of the drug had

been removed

Dollery advises the doses given in the

table, down to 20 mL/minute, but nothing
after that.
Micromedex gives the following

recommendations:
GFR: 30–60 mL/min 150 mg twice daily
GFR: 10–30 mL/min 150 mg once daily
GFR:

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min 150 mg alternate days

Tags: post-by-auto-php